This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Could AbbVie's Buyout of Shire Make It a New Dividend Aristocrat?

Stocks in this article: ABBVABTSHPMDTCOV

NEW YORK (TheStreet) -- AbbVie  (ABBV) finally agreed to terms for a $54.8 billion buyout of Shire (SHP) Friday. In the process, AbbVie has become the largest U.S company to ever take over a foreign company in a bid to lower its tax rate, a move known as inversion. This was the fifth offer AbbVie had made to Shire before being accepted.

Irish companies have become a hot-bed of activity recently as U.S corporations use the much lower Irish tax rate to play accounting games and reduce their tax exposure. And TheStreet's John Mason analyzed the growing practice of inversion yesterday.

But is this move a good idea for the companies, aside from the tax rate?

Airlines Flew Over Ukraine Until Malaysia Crash Despite Danger Signs

Australia's Carbon Tax Experiment Goes Up in Smoke

5 Biggest Amusement Park Chains of Summer 2014

Why For-Profit Education Institutions Should Be Sent to Detention

The Shire buyout is expected to reduce AbbVie's tax rate from 22% to 13%, no small amount given the size of the combined company after the merger.

But according to AbbVie CEO Richard Gonzalez, "This is a transaction that we believe has excellent strategic fit, well beyond the tax impact. We wouldn't be doing it if it was just for the tax impact."

And there is merit in the AbbVie "strategic fit" argument.

AbbVie will benefit from Shire's revenue right away. Shire projects its revenue will double by 2020 to $10 billion. With $5 billion in revenue for the last year, Shire has posted 17% year-over-year quarterly revenue growth. Levered free cash flow is very strong for Shire, coming in at over $1 billion last year.

This added cash flow could be used by AbbVie to easily increase the dividend it pays, currently $1.68 per year -- a 3% yield. As of now, AbbVie pays out 53% of its annual earnings per share in dividends. With the deal expected to be positive for EPS, along with the extra free cash flow, a bonus to this merger could be an increase in the dividend.

This deal will also help AbbVie to reduce its reliance on its blockbuster arthritis drug Humira, which loses patent protection next year.

Shire brings to the table a portfolio of drugs in the rare disease market. Those drugs are attracting more attention in recent years. Shire is a leader in the ADHD market, with the leading drugs Adderal XR, Intuniv and Vyvanse. These drugs helped generate almost 40% of the company's revenue last year. The combined company will now have 15 drugs in Phase 3 trials.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,712.76 +34.86 0.21%
S&P 500 1,952.48 +1.66 0.09%
NASDAQ 4,461.1930 +8.4010 0.19%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs